A 510(k) is a premarket notification submitted to FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device. The standard is comparative: the submitter must show the same intended use and either the same technological characteristics or different characteristics that do not raise new questions of safety and effectiveness [1]. Clearance is not a certification of independent safety, but an order finding substantial equivalence and permitting commercial distribution [5]. For regulatory affairs teams, the practical work is therefore predicate selection, comparison documentation, and submission format compliance. The three submission programs—Traditional, Special, and Abbreviated—share the same user fee but differ in evidentiary structure and appropriate use cases [2][7]. Understanding those distinctions, along with the acceptance review threshold, determines whether a submission enters substantive review or is refused before evaluation begins [6].
Who Must Submit and What Substantial Equivalence Requires
The FD&C Act and 21 CFR 807 do not name a specific party; they define triggering actions. Domestic manufacturers introducing a device to the U.S. market, specification developers, and certain other categories must submit a 510(k) unless the device is exempt under the limitations in .9 of the device classification regulation chapters [1][4]. Contract manufacturers producing devices to another firm's specifications are not required to submit, because the specification developer holds that obligation [4]. Component manufacturers are also outside the requirement unless components are promoted to end users as replacement parts [4].
Substantial equivalence has two possible paths. The first requires the same intended use and the same technological characteristics as the predicate. The second permits different technological characteristics, provided the device does not raise different questions of safety and effectiveness and the submitted information demonstrates the device is as safe and effective as the predicate [1][4]. A legally marketed predicate can be a preamendments device, a device reclassified from Class III, a device previously found substantially equivalent through 510(k), or a device authorized through De Novo classification that is not exempt from premarket notification [4][5].
Traditional, Special, and Abbreviated Submission Programs
FDA recognizes three 510(k) submission types. The Traditional 510(k) can be used for any original submission or for a change to a previously cleared device, making it the default path when no alternative program fits [2][7]. The Special and Abbreviated programs were developed in 1998 to support review of certain submissions, and FDA split the original New 510(k) Paradigm guidance into separate documents for each program in 2019 [2][7]. All three programs carry the same user fee, and FDA states that the fee should not be sent with the submission [2][7].
The Special 510(k) is appropriate when a modification to a cleared device can be evaluated using well-established methods and the results can be reviewed in a summary or risk analysis format. FDA notes that a Special 510(k) would generally not be appropriate for devices that manufacture a biological product at the point of care, because no well-established evaluation method would likely exist [7]. The Abbreviated 510(k) is available when the submission relies on FDA guidance documents, demonstration of compliance with special controls, or voluntary consensus standards. In that program, firms provide summary reports on the use of guidance documents or special controls, or declarations of conformity to recognized standards, rather than full underlying test reports, though the required elements of 21 CFR 807.87 still apply [7].
Assembling the Required Content Elements
A Traditional 510(k) must include the Medical Device User Fee Cover Sheet (Form FDA 3601), a cover letter, a 510(k) summary or statement, a truthful and accuracy statement, proposed labeling, specifications including engineering drawings and photos, performance data from bench, animal, or clinical testing if applicable, sterilization information if applicable, and any device-specific guidance documents [3]. The 510(k) summary, if chosen under 21 CFR 807.92, must be sufficiently detailed to provide an understanding of the basis for the substantial equivalence determination, and FDA will accept summaries or amended summaries until it issues a determination [3].
The labeling section should include copies of all proposed labels, package inserts, service manuals, instructions for use, and advertising or promotional materials. Directions for use must include a specific intended use statement and any warnings, contraindications, or limitations [3]. Additional information may be required if the device contains software, contains a color additive, is labeled sterile, or emits electronic radiation [3].
Predicate Selection and the Comparison Table
FDA recommends identifying a primary predicate most similar to the subject device with respect to indications for use and technological characteristics, and including the predicate's 510(k) number where possible [2]. Under certain circumstances, a submitter may claim substantial equivalence to more than one predicate [2]. The comparison must address intended use, indications for use, target population, anatomical site, use environment, energy delivered, human factors, design, performance, standards met, materials, biocompatibility, sterility, and electrical, mechanical, chemical, thermal, and radiation safety [3].
The comparison discussion should elaborate on similarities identified in the table and explain why any differences do not affect safety and effectiveness [3][6]. The acceptance checklist requires a predicate device identifier, which may be a 510(k) number, De Novo number, reclassified PMA number, or classification regulation reference if exempt [6]. When labeling or specific technological characteristics such as materials or dimensions are unchanged from the predicate, the submission should state clearly that no changes were made [6].
Acceptance Review and the eSTAR Submission Requirement
Before substantive review, FDA applies a Refuse to Accept policy to determine whether a 510(k) meets a minimum threshold of acceptability. The purpose is to focus review resources on complete submissions and provide a more efficient approach to ensuring that safe and effective medical devices reach patients as quickly as possible [6]. The acceptance checklist includes items such as a detailed description of all device modifications with rationale, a predicate device identifier, and a comparison of the subject and predicate devices with discussion of why differences do not impact safety and effectiveness [6]. A submission that fails this threshold is not accepted for substantive review [6].
Starting October 1, 2023, all 510(k) submissions unless exempted must be submitted as electronic submissions using eSTAR [2][5]. FDA accepts eSTAR or eCopy premarket submissions online through the CDRH Customer Collaboration Portal [2][5]. Mailed submissions on electronic storage media were only accepted if received before October 1, 2023 [2]. FDA does not return the submission or any copies, so submitters should retain a complete copy for their records [2].
A Hypothetical Evaluation: Modified Orthopedic Cutting Guide
Consider a regulatory team evaluating a change to a cleared single-use orthopedic cutting guide. The change replaces a stainless steel component with a titanium alloy of different dimensions. The team would first determine whether the change requires a new 510(k) by reviewing the guidance on deciding when to submit a 510(k) for a change to an existing device [7]. Some device changes may be implemented without submission of a new 510(k) [7]. If a new submission is required, the team must decide between Traditional and Special. A Special 510(k) would be appropriate only if the method to evaluate the material and dimensional change is well-established and the results can be reviewed in a summary or risk analysis format [7].
The comparison table would need to address materials, dimensions, biocompatibility, and mechanical safety against the predicate [3]. If the titanium alloy introduces a different biocompatibility profile, the team would need to provide either testing data or a statement that biocompatibility testing is not needed with a rationale that considers all relevant endpoints, such as materials and manufacturing or processing being identical to the predicate [6]. This hypothetical is a suggested workflow for structuring an internal evaluation; it does not establish that any specific material change would or would not require a new 510(k), which remains a case-specific determination under FDA guidance [7].
Sources & references
- Premarket Notification 510(k) · U.S. Food and Drug Administration
- How to Prepare a Traditional 510(k) | FDA · www.fda.gov
- Content of a 510(k) | FDA · www.fda.gov
- Premarket Notification 510(k) | FDA · www.fda.gov
- Premarket Notification 510(k) | FDA · fda.gov
- Refuse to Accept Policy for 510(k)s · www.fda.gov
- 510(k) Submission Programs | FDA · www.fda.gov